Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Interest Expenses (2022 - 2026)

Indivior Pharmaceuticals has reported Interest Expenses over the past 5 years, most recently at $7.0 million for Q1 2026.

  • For Q1 2026, Interest Expenses fell 41.67% year-over-year to $7.0 million; the TTM value through Mar 2026 reached $40.0 million, up 122.22%, while the annual FY2025 figure was $45.0 million, 9.76% up from the prior year.
  • Interest Expenses for Q1 2026 was $7.0 million at Indivior Pharmaceuticals, up from $6.0 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $15.0 million in Q2 2025 and troughed at -$14.0 million in Q4 2024.
  • A 5-year average of $312500.0 and a median of -$500000.0 in 2022 define the central range for Interest Expenses.
  • On a YoY basis, Interest Expenses climbed as much as 210.0% in 2024 and fell as far as 55.56% in 2024.
  • Year by year, Interest Expenses stood at -$8.0 million in 2022, then dropped by 12.5% to -$9.0 million in 2023, then tumbled by 55.56% to -$14.0 million in 2024, then surged by 142.86% to $6.0 million in 2025, then rose by 16.67% to $7.0 million in 2026.
  • Business Quant data shows Interest Expenses for INDV at $7.0 million in Q1 2026, $6.0 million in Q4 2025, and $12.0 million in Q3 2025.